Fed. Circ. Says Generics Deals Exclude Endo's New Patents
The Federal Circuit ruled Monday that settlements allowing Roxane Laboratories Inc. and Actavis Inc. to sell generic versions of Endo Pharmaceuticals Inc.'s painkiller Opana ER did not include licenses for later...To view the full article, register now.
Already a subscriber? Click here to view full article